Margarida Maia, PhD,  science writer—

This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…

Meitheal Pharmaceuticals has entered into an agreement with Xentria to market XTMAB-16, the investigational treatment for pulmonary sarcoidosis, should it be approved in the future. Under the terms of the agreement, Meitheal gains the sole rights to sell and distribute XTMAB-16 in North America. Xentria retains the…

Bellerophon Therapeutics is working toward launching a new Phase 2 trial to test INOpulse, its experimental device for inhaled nitric oxide, in people who develop pulmonary hypertension as a complication of sarcoidosis (PH-Sarc). The announcement was part of a company’s clinical program update that stated…

The Foundation for Sarcoidosis Research (FSR) has trained its first group of volunteer patients tasked with educating and championing better treatments and outcomes for people living with sarcoidosis in the U.S. The 60 newly trained volunteer leaders will team up with and support members of the foundation’s…

Off-label use of TNF-alpha inhibitors may help some people with hard-to-treat sarcoidosis ease their symptoms or prevent them from getting worse, according to a meta-analysis study. Data also showed that these inhibitors, particularly Remicade (infliximab), may work slightly better for patients who have symptoms of sarcoidosis…

Adalimumab — a medication that blocks the pro-inflammatory TNF-alpha protein — safely and effectively eased symptoms of cardiac sarcoidosis in seven adults, allowing them to reduce or discontinue their use of corticosteroids, a study reports. The therapy also promoted a rise in the number of lymphocytes, a type of…

The chance of developing sarcoidosis is nearly halved in those with obstructive sleep apnea (OSA), a sleeping disorder wherein breathing slows or stops repeatedly and for short times during sleep, according to a large study involving U.S. veterans. The findings point to OSA as a protective factor for sarcoidosis.

Patients with sarcoidosis of the heart, called cardiac sarcoidosis, with no other organ involved have more advanced symptoms at their first doctor visit than those with prior involvement of organs other than the heart, a study found. With time, they also develop a type of irregular heartbeat called ventricular…

African Americans with advanced-stage pulmonary sarcoidosis who are taking Acthar Gel (repository corticotropin injection) may see their symptoms ease and be able to reduce the use of other medications, according to new findings. The findings were pulled from a new subgroup analysis of a real-world study that…

Poorer lung function and a higher body mass index (BMI), a measure indicating obesity, are significantly associated with a lower self-reported quality of life in people with sarcoidosis, a German study found. Of note, the tool used to assess quality of life — called the King’s Sarcoidosis Questionnaire or…